EMPA-REG OUTCOME trial shows Jardiance can be cost effective in type 2 diabetes patients with CV disease plus diabetic kidney disease

Boehringer and Eli Lilly announced results from a new cost-effectiveness analysis of the EMPA-REG OUTCOME trial with Jardiance (empagliflozin) in a subgroup of 2,250 people with type 2 diabetes and established cardiovascular disease who also have diabetic kidney disease. Results suggest that treatment with empagliflozin, in addition to standard of care, leads to fewer cardiovascular and renal events, and has the potential to be a cost-effective treatment option for people with type 2 diabetes and diabetic kidney disease from the perspective of payers in the US.

The modeling and simulation of cost effectiveness was performed using the cost per episode of certain diabetes-related clinical events and health utilities in the US associated with these events. Patients receiving empagliflozin were predicted to experience fewer of these clinical events, including progression of albuminuria (presence of the protein albumin in the urine), composite renal outcomes, hospitalisation for heart failure and cardiovascular deaths. Additionally, patients taking empagliflozin with standard of care were projected to survive 1.37 years longer compared to standard of care alone. This sensitivity analyses showed that, from a US perspective, empagliflozin could be a cost effective option for 99 percent of people with type 2 diabetes and cardiovascular disease at a threshold of $100,000/quality-adjusted life years (QALYs). The results were presented at the ISN World Congress of Nephrology.